Advertisement
Innate Pharma S.A. (IPHYF)
OTC Markets OTCPK - OTC Markets OTCPK Delayed Price. Currency in USD
Follow
At close: 04:00PM EDT
| Previous Close | 0.0000 |
| Open | 2.1300 |
| Bid | 1.5500 x 40000 |
| Ask | 2.5300 x 40000 |
| Day's Range | 2.2000 - 2.2000 |
| 52 Week Range | 1.9300 - 2.8950 |
| Volume | |
| Avg. Volume | 110 |
| Market Cap | 181.735M |
| Beta (5Y Monthly) | 0.79 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.4600 |
| Earnings Date | Sep 12, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Business WireInnate Pharma Appoints Jonathan Dickinson as New Chief Executive Officer and Chairman of the Executive Board
MARSEILLE, France, October 14, 2024--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today announced that its supervisory Board has appointed Jonathan Dickinson as the Company’s new Chief Executive Officer (CEO) and Chairman of the Executive Board, effective November 1, 2024. Jonathan Dickinson succeeds Hervé Brailly, co-founder of the Company, who was interim CEO, during the search process.
Business WireInnate Pharma to Host KOL Scientific Symposium on Immunotherapy in New York on October 3, 2024
MARSEILLE, France, September 30, 2024--Innate Pharma to host KOL scientific symposium on immunotherapy in New York on October 3, 2024
Advertisement
Advertisement
Advertisement
© 2024 Yahoo. All rights reserved.